Biotech AI startup Sight Diagnostics gets $27.8M to speed up blood tests

Sight Diagnostics, an Israeli medical devices startup that's using AI technology to speed up blood testing, has closed a $27.8 million Series C funding round. The company has built a desktop machine, called OLO, that analyzes cartridges manually loaded with drops of the patient's blood -- performing blood counts in situ. The new funding is led by VC firm Longliv Ventures, also based in Israel, and a member of the multinational conglomerate CK Hutchison Group. Sight Diagnostics said it was after strategic investment for the Series C -- specifically investors that could contribute to its technological and commercial expansion. And on that front CK Hutchison Group's portfolio includes more than 14,500 health and beauty stores across Europe and Asia, providing a clear go-to-market route for the company's OLO blood testing device.